Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of WT1 peptides to induce anti-leukemia immune responses following autologous or allogeneic transplantation for AML [acute myelogenous leukaemia] CML [chronic myelogenous leukaemia], ALL [acute lymphoblastic leukaemia], MDS [myelodysplastic syndrome], and B Cell malignancies.

Next Previous
Trial Profile

A phase I study of WT1 peptides to induce anti-leukemia immune responses following autologous or allogeneic transplantation for AML [acute myelogenous leukaemia] CML [chronic myelogenous leukaemia], ALL [acute lymphoblastic leukaemia], MDS [myelodysplastic syndrome], and B Cell malignancies.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cancer vaccines; Cancer vaccines; Granulocyte-macrophage colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors; Montanide ISA-51; Montanide ISA-51
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 10 Dec 2013 Biomarkers information updated
  • 20 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 20 Sep 2013 Planned end date changed from 1 Jun 2014 to 1 Oct 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top